Arterial Tone Influence on Cardiac Output Measured by PRAM
Influence of Arterial Tone Changes on Cardiac Output Measurement by Pressure Recording Analytical Method
1 other identifier
observational
31
1 country
1
Brief Summary
This study evaluates the role of arterial tone in the accuracy of cardiac output (CO) measurement by Pressure Recording Analytical Method (PRAM). Patients receiving noradrenaline who need for clinical reason to change the noradrenaline dose will be enrolled. We use echocardiography as reference method of CO measurement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 29, 2019
CompletedFirst Posted
Study publicly available on registry
April 3, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2020
CompletedMarch 25, 2020
March 1, 2020
5.9 years
March 29, 2019
March 23, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Changes of cardiac output after variation of noradrenaline dose: ECO versus PRAM
Agreement between echocardiography and PRAM in CO measurement during arterial tone changes induced by different dose of noradrenaline
Before and 30 minutes after noradrenaline dose variation
Interventions
CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
Eligibility Criteria
Critically ill patients admitted to intensive care unit that need variation of noradrenaline dose for clinical reason.
You may qualify if:
- invasive blood pressure monitoring on site
- need to start or change the dose of noradrenaline infusion for clinical reason
You may not qualify if:
- age \<18
- arrhythmia
- severe valvular insufficiency
- pregnancy
- low quality arterial signal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona
Ancona, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Abele Donati, MD, PhD
Università Politecnica delle Marche
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 29, 2019
First Posted
April 3, 2019
Study Start
March 1, 2014
Primary Completion
February 1, 2020
Study Completion
February 1, 2020
Last Updated
March 25, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share
IPD will not be shared with other researchers.